Dexycu receives permanent J-code

CMS has assigned a permanent reimbursement J-code for Dexycu through the Healthcare Common Procedure Coding System, EyePoint Pharmaceuticals announced in a press release.

Dexycu (dexamethasone intraocular suspension) 9%, the first FDA-approved, single-dose, sustained-release intracameral steroid for the treatment of postoperative inflammation, will have the code J1095, which will become effective Jan. 1, 2019. The code will replace the C-code C9034 that was previously issued for Dexycu.

“The issuance of a specific and permanent J-code for Dexycu is another key milestone for the company that allows for a convenient and simplified reimbursement process that is familiar to administering physicians and the greater insurance community,” EyePoint President and CEO Nancy Lurker said in the release.

The company expects to commercially launch Dexycu in the first half of 2019.

CMS has assigned a permanent reimbursement J-code for Dexycu through the Healthcare Common Procedure Coding System, EyePoint Pharmaceuticals announced in a press release.

Dexycu (dexamethasone intraocular suspension) 9%, the first FDA-approved, single-dose, sustained-release intracameral steroid for the treatment of postoperative inflammation, will have the code J1095, which will become effective Jan. 1, 2019. The code will replace the C-code C9034 that was previously issued for Dexycu.

“The issuance of a specific and permanent J-code for Dexycu is another key milestone for the company that allows for a convenient and simplified reimbursement process that is familiar to administering physicians and the greater insurance community,” EyePoint President and CEO Nancy Lurker said in the release.

The company expects to commercially launch Dexycu in the first half of 2019.